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The relationship between sex-related factors and multiple sclerosis (MS), nowadays widely recognized, has led to the idea that sex hormones, easily available at low cost, could be promising therapeutic solutions for MS. However, their putative impact is not univocal: the two main oestrogen receptors (ERα and ERβ) can act synergistically or antagonistically depending on the tissue and in MS they could modulate both inflammation (through ERα activation on peripheral and central nervous system (CNS) resident immune cells and astrocytes) and repairing pathways (through ERβ activation on oligodendrocytes, astrocytes and monocytes). 1 By contrast, progesterone and androgens have not been shown to reverse inflammation but both demonstrated potential to enhance myelin repair in experimental models. 2, 3 Supporting the pros of pushing sex hormones towards phase 3, R Voskul points out that estriol is to date the most promising candidate that could be used as a disease-modifying therapy (DMT). Its previous evaluation in pilot phase 2 studies described a beneficial impact on magnetic resonance imaging (MRI) and relapse rate and doses needed to reach clinical effects are well tolerated (a condition not achieved for estradiol). The preferential binding to ERβ also suggests a safer oncological risk profile. However, as discussed by Houtchens and Desai, the total number of subjects included remains very low, and the results were not fully consistent across studies. Moreover, the putative consequences of long-term exposure to sex hormones, regarding possible oncological or thromboembolism risk, are not yet well known. To further characterize the potential of estriol to be used as a DMT, there is still a need to demonstrate equivalence or advantage over available drugs, regarding not only cost, but also efficacy and/or risk, through a larger comparative trial. However, due to their major cost, phase 3 trials are unlikely to be sponsored at this stage. To circumvent this blocking issue, comparative phase 2 trials may represent a promising solution: meta-analysis of past therapeutic trials in MS convincingly showed that the efficacy of immune-active drugs on MRI-based metrics such as T2 lesions or gadolinium-enhanced lesions in phase 2 is strongly predictive of the level of efficacy on relapse rate in phase 3, 4 opening the perspective of comparative phase 2 studies based on MRI metrics. Even so, assessing safety profile would still require larger cohorts, such as close post-marketing surveillance.
Sex hormones were also shown to promote myelin repair and neuroprotection in animal models, a yet unmet need in MS. 1, 3 However, none has really reached the level of evidence needed to start a phase 3 trial in this indication. An increasing number of repurposed compounds, including hormones, are nowadays candidate for repair trials in MS, but the optimal design to validate their efficacy remains challenging, as we still lack a sensitive and specific measure of remyelination. Pilot repair studies have mainly focused on the optic nerve, an anatomic region that has intrinsically low remyelination capacities. Imaging outcomes such as myelin positron emission tomography (PET) or advanced MRI sequences specific for myelin may enable to quantify remyelination with an improved sensitivity. Interestingly, individual remyelination profiles measured by PET were shown to be heterogeneous across patients with MS, leading to a potential bias that would need to be compensated, for instance, by including a run-in period in trials. 5 A possible therapeutic design, applicable to sex hormones, could therefore combine advanced imaging (including myelin and volumetric measures) and neurophysiology outcomes in phase 2 trials, with a run-in period preceding the comparative phase.
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